Project Tree Structure: (Markdown files only)

01-problem.md
02-solution.md
03-platform.md
benefits
├── cost-savings-from-decentralized-clinical-trials.md
├── faster-progress.md
├── improving-treatment-affordability-and-accessibility.md
├── lower-costs-of-validated-observational-research-for-efficacy.md
├── lower-costs.md
├── lower-drug-prices.md
├── more-cures-and-less-lifelong-attempts-at-masking-symptoms.md
├── overall-economic-benefits.md
├── patient-participation.md
└── time-to-treatment.md
blueprint
├── blueprint-gas.md
├── blueprint-high-level.md
├── blueprint-sitemap.md
├── blueprint-strategy.md
├── blueprint-summary.md
└── blueprint.md
clinical-trials
├── decentralized-methods
│   └── desci-ai-dao.md
├── methodologies
│   └── definitions.md
└── protocols
│   └── crowdsourcing-longevity-research.md
community
├── community_volunteers
│   └── README.md
├── CONTRIBUTING.md
├── developers
│   └── README.md
├── funding_sources
│   └── README.md
├── governance
│   └── dfda-collaboration-framework.md
├── healthcare_providers
│   └── README.md
├── industry_stakeholders
│   └── README.md
├── open-source-projects
│   └── open-source-projects.md
├── opencures.md
├── partners
│   ├── ageless-partners.md
│   └── README.md
├── patient_advocacy
│   ├── crowdsourcing-cures.md
│   └── README.md
├── projects
│   └── README.md
├── README.md
├── regulatory_legal
│   └── README.md
├── researchers
│   └── README.md
├── resources
│   └── README.md
├── templates
│   ├── open_source_project.md
│   ├── partner_introduction.md
│   └── project_proposal.md
└── weavechain.md
conditions
└── scabies.md
dfda-sitemap.md
disease-eradication-act
├── disease-eradication-act-cost-benefit-analysis.md
├── disease-eradication-act-details.md
├── disease-eradication-act-summary.md
└── disease-eradication-act.md
economic-models
├── benfits-of-over-the-counter-classification.md
├── cost-benefit-analysis-for-drug-classification.md
├── dfda-cost-benefit-analysis.md
├── nih-grant-efficiency-analysis.md
└── quantitative-value-medical-treatment.md
economic-models.md
features
├── analytics
│   └── causal-inference-analysis.md
├── browser-extension
│   └── browser-extension.md
├── clinipedia
│   └── clinipedia.md
├── data-analysis.md
├── data-collection-plugins.md
├── data-collection.md
├── data-import.md
├── data-silo-api-gateways.md
├── decision-support-notifications.md
├── desci-exchange.md
├── digital-twin-safe.md
├── digital-twin-skeleton-key-nft.md
├── fdai
│   ├── drug-classification.md
│   ├── fdai-act.md
│   ├── fdai-system-prompt.md
│   ├── fdai.md
│   ├── petition.md
│   ├── presentation.md
│   ├── scenario.md
│   └── simulated-conversation.md
├── global-health-unifier-agent.md
├── human-file-system-protocol.md
├── life-force-score-nft.md
├── no-code-app-builder.md
├── notifications.md
├── observational-studies.md
├── optomitron-ai-agent.md
├── outcome-labels-plugin.md
├── outcome-labels.md
├── personal-fda-nodes.md
├── predictor-search-engine.md
├── root-cause-analysis-plugin.md
├── root-cause-analysis-reports.md
└── study-review-agent.md
home.md
interventions
├── cerebrolysin.md
├── focused-ultrasound.md
└── memantine.md
logical-proof-to-focus-on-dfda.md
one-pager.md
problems
├── bias-against-approval.md
├── clinical-research-is-expensive.md
├── clinical-research-is-slow.md
├── clinical-research-is-too-expensive.md
├── conflicts-of-interest.md
├── deaths-due-to-us-regulatory-drug-lag.md
├── difficulty-participating.md
├── drug-lag.md
├── fda-decisions-not-based-on-cost-benefit-analysis.md
├── insufficient-roi-to-discover-treatments-for-rare-diseases.md
├── monopolies.md
├── negative-results-are-never-published.md
├── no-comparative-effectiveness-rankings.md
├── no-data-on-unpatentable-molecules.md
├── no-incentive-to-discover-benefits-of-off-patent-treatments.md
├── no-long-term-outcome-data.md
├── people-with-rare-disease-are-severely-punished.md
├── pre-determining-clinical-endpoints-requires-psychic-powers.md
├── problems-in-clinical-research.md
├── slowed-growth-in-life-expectancy.md
├── statistics
│   ├── cost-per-participant.md
│   ├── cost-per-treatment.md
│   ├── deaths-due-to-drug-lag.md
│   ├── percent-excluded-from-trials.md
│   ├── percent-of-diseases-with-fda-approved-treatments.md
│   ├── treatments-tested.md
│   ├── uncured-people.md
│   └── years-since-last-cure.md
├── trials-often-arent-representative-of-real-patients.md
├── unpatentable-treatments.md
├── unrepresentative-participants.md
├── we-know-nothing.md
└── we-only-know-the-effects-of-0000000002-of-potential-therapies.md
proposals
├── dfda-act.md
├── health-savings-sharing.md
└── use-github-for-task-management.md
reference
├── 12-references.md
├── cost-barriers
│   ├── 21-data-sources.md
│   ├── 211-publically-available-literature.md
│   ├── 212-discussions-with-experts-fda-personnel-drug-sponsors-contract-research-organizations-cros-and-academic-clinical-research-centers.md
│   ├── 213-medidata-solutions-databases.md
│   ├── 22-conceptual-framework.md
│   ├── 23-operational-model.md
│   ├── 24-model-parameters.md
│   ├── 31-costs-by-therapeutic-area.md
│   ├── 32-costs-by-trial-phase.md
│   ├── 33-costs-by-cost-component.md
│   ├── 34-conclusions.md
│   ├── 41-high-financial-cost.md
│   ├── 42-lengthy-timelines.md
│   ├── 43-difficulties-in-recruiting-and-retaining-participants.md
│   ├── 44-increasing-competition-for-qualified-investigators-and-sites.md
│   ├── 45-regulatory-and-administrative-barriers.md
│   ├── 451-regulations-protecting-human-research-subjects-and-their-privacy.md
│   ├── 452-safety-reporting-requirements-for-investigational-new-drugs-inds-and-biologics-21-cfr-312.md
│   ├── 453-regulations-for-multiple-jurisdictions.md
│   ├── 454-conservative-regulatory-climate.md
│   ├── 455-lack-of-clear-regulatory-pathways-and-guidance-for-some-therapeutic-areas.md
│   ├── 456-barriers-related-to-the-review-process.md
│   ├── 46-drug-sponsor-imposed-barriers.md
│   ├── 461-administrative.md
│   ├── 462-study-design.md
│   ├── 463-data-and-site-monitoring.md
│   ├── 464-serious-adverse-events-saes-reporting-for-investigational-new-drugs-and-biologics-inds-21-cfr-312.md
│   ├── 47-disconnect-between-clinical-research-and-medical-care.md
│   ├── 48-barriers-at-academic-institutions.md
│   ├── 49-barriers-related-to-the-globalization-of-clinical-research.md
│   ├── 51-use-of-electronic-health-records-ehr.md
│   ├── 52-relaxing-trial-enrollment-restrictions.md
│   ├── 53-simplified-clinical-trial-protocols-and-reduced-amendments.md
│   ├── 54-reduced-source-data-verification-sdv.md
│   ├── 55-wider-use-of-mobile-technologies-such-as-electronic-data-capture-edc.md
│   ├── 56-wider-use-of-lower-cost-facilities-andor-at-home-testing.md
│   ├── 57-priority-reviewpriority-review-vouchers.md
│   ├── 58-improvements-in-fda-review-process-efficiency-and-more-frequent-and-timely-interactions-with-fda.md
│   ├── 59-conclusions.md
│   └── executive-summary
│   │   ├── e1-clinical-trial-decision-making-model.md
│   │   ├── e2-analysis-of-costs.md
│   │   ├── e3-barriers-to-clinical-trials.md
│   │   ├── e31-high-financial-cost.md
│   │   ├── e32-lengthy-timelines.md
│   │   ├── e33-difficulties-in-recruiting-and-retaining-participants.md
│   │   ├── e34-increasing-competition-for-qualified-investigators-and-sites.md
│   │   ├── e35-regulatory-and-administrative-barriers.md
│   │   ├── e36-drug-sponsor-imposed-barriers.md
│   │   ├── e37-disconnect-between-clinical-research-and-medical-care.md
│   │   ├── e38-barriers-at-academic-institutions.md
│   │   ├── e39-barriers-related-to-the-globalization-of-clinical-research.md
│   │   └── e4-analysis-of-barriers-to-clinical-trials.md
├── data-storage-costs.md
├── historical-evidence-supporting-decentralized-efficacy-trials.md
├── historical-evidence-supporting-real-wold-efficacy-trials.md
├── history-of-medical-regulation-and-clinical-research.md
├── impact-of-innovative-medicines-on-life-expectancy.md
├── nih-recover-initiative.md
├── otc-drugs.md
├── pragmatic-trials.md
├── recovery-trial.md
├── references.md
├── Research-and-Development-in-the-Pharmaceutical-Industry.md
└── value-of-new-treatment.md
reference-databases
├── biomarker-databases.md
├── diseases.md
├── food-databases.md
├── medication-databases.md
├── README.md
├── supplement-databases.md
└── units.md
regulatory
├── cost-benefit-analysis-framework-for-rational-drug-classification.md
├── dfda-executive-order.md
└── hhs-policy-recommendations.md
scripts
└── README.md
SITEMAP.md
strategy
├── implementation-plan.md
├── patient-industrial-complex.md
├── roadmap.md
├── strategy-comparison.md
└── war-on-disease-strategy.md
wiki
└── interventions
│   └── brain-computer-interfaces-for-depression.md
